The management of poor-prognosis, non-seminomatous germ-cell tumours

Clinical Oncology

Volumn 17, Issue 7, 2005, Pages 543-552

  Sirohi, B ^a   Huddart, Robert A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Autotransplantation; BEP; Early response; Non seminomatous germ cell tumours; Poor prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; HYDROCORTISONE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; KIDNEY INJURY; LEUKEMIA; MALE; MALE GENITAL SYSTEM SURGERY; MAXIMUM PERMISSIBLE DOSE; NON SEMINOMATOUS GERMINOMA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SIDE EFFECT; TESTIS CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; TESTICULAR NEOPLASMS;

EID: 25144467838     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.07.008     Document Type: Article

References (53)

1. International Germ Cell Cancer Collaborative Group International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594-603
2. C. Kollmannsberger C. Nichols C. Meisner F. Mayer L. Kanz C. Bokemeyer Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling Ann Oncol 11 2000 1115-1120
3. M.R. van Dijk E.W. Steyerberg S.P. Stenning J.D. Habbema Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: A validation study Ann Oncol 15 2004 1400-1405
4. D. Sonneveld H. Hoekstra W. van de Graaf et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era Cancer 91 2001 1304-1315
5. N. Aass O. Klepp E. Cavallin Stahl et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicenter experience J Clin Oncol 9 1991 818-826
6. M.J. Harding J. Paul C.R. Gillis S.B. Kaye Management of malignant teratoma: Does referral to a specialist unit matter? Lancet 314 1993 999-1002
7. L. Collette R. Sylvester S. Stenning et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma J Natl Cancer Inst 91 1999 839-846
8. M.J. Stevens A.R. Norman D.P. Dearnaley A. Horwich Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma J Clin Oncol 13 1995 87-92
9. R. de Wit R. Sylvester C. Tsitsa et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 1997 432-435
10. K. Fizazi D.M. Prow K.A. Do et al. Alternating dose-sense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors Br J Cancer 86 2002 1555-1560
11. M. Mazumdar D.F. Bajorin J. Bacik G. Higgins R.J. Motzer G.J. Bosl Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy J Clin Oncol 19 2001 2534-2541
12. S.B. Kaye G.M. Mead S. Fossa et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study J Clin Oncol 16 1998 692-701
13. C.R. Nichols P.J. Catalano E.D. Crawford N.J. Vogelzang L.H. Einhorn P.J. Loehrer Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study J Clin Oncol 16 1998 1287-1293
14. R. de Wit M. Louwerens P.H. de Mulder J. Verweij S. Rodenhuis J. Schornagel Management of intermediate-prognosis germ-cell cancer: results of phase I/II study of Taxol-BEP Int J Cancer 83 1999 831-833
15. R.A. Huddart A.J. Birtle Recent advances in the treatment of testicular cancer Expert Rev Anticancer Ther 5 2005 123-138
16. M. Bower E. Newlands L. Holden G. Rustin R. Begent Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy Ann Oncol 8 1997 477-483
17. C. Bokemeyer A. Gerl P. Schoffski et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer J Clin Oncol 17 1999 512-516
18. C. Chevreau J.P. Droz J.L. Pico et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours Eur Urol 23 1993 213-218
19. J.R. Germa-Lluch X. Garcia del Muro J.M. Taberno et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GG) Ann Oncol 10 1999 289-293
20. J.A. Christian R.A. Huddart A. Norman et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors J Clin Oncol 21 2003 871-877
21. N. Bhala J.M. Coleman C.R. Radstone et al. The management and survival of patients with advanced germ-cell tumours: Improving outcome in intermediate and poor prognosis patients Clin Oncol 16 2004 40-47
22. J.P. Droz S. Culine J. Bouzy Preliminary results of a randomized trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin/vinblastin, bleomycin (CISCA/VB) for patients (Pts) with intermediate- and poor-risk metastatic non seminomatous germ-cell tumors (NSGCT) [Abstract 690] ASCO 2001; Thirty-Seventh Annual Meeting, May 12-15, 2001 2001 American Society of Clinical Oncology San Francisco, CA 173a
23. H.J. Schmoll C. Kollmannsberger B. Metzner et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German Testicular Cancer Study Group J Clin Oncol 21 2003 4083-4091
24. C. Bokemeyer N. Schleucher B. Metzner et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: A prospective trial Br J Cancer 89 2003 29-35
25. C. Bokemeyer A. Harstrick J. Beyer The use of dose-intensified chemotherapy in the treatment of metastatic non seminomatous testicular germ cell tumors Semin Oncol 25 2 Suppl 4 1998 24-32
26. S. Fosså S. Stenning A. Gerl et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1999 1392-1399
27. J. McCaffrey M. Mazumdar D. Bajorin G. Bosl V. Vlamis R. Motzer Ifosfamide and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival J Clin Oncol 15 1997 2559-2563
28. P. Loehrer R. Gonin C. Nichols T. Weathers L. Einhorn Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 16 1998 2500-2504
29. M. Shahidi A. Norman J. Nicholls D. Dearnaley A. Horwich R. Huddart Late recurrence in 1263 men with testicular germ cell tumours: Multivariate analysis of risk factors and implications for management Cancer 95 2002 520-530
30. A. Gerl C. Clemm N. Schmeller M. Hentrich R. Lamerz W. Wilmanns Late relapse of germ cell tumors after cisplatin-based chemotherapy Ann Oncol 8 1997 41-47
31. C. Kollmannsberger O. Rick H.G. Derigs et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group J Clin Oncol 20 2002 2031-2037
32. L. Einhorn M. Stender S. Williams Phase II trial of gemcitabine in refractory germ cell tumors J Clin Oncol 17 1999 509-511
33. H.S. Puc D.F. Bajorin G.J. Bosl A. Amsterdam R.J. Motzer Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors Invest New Drugs 13 1995 163-165
34. G. Varuni Kondagunta J. Bacik L. Schwartz et al. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors Invest New Drugs 22 2004 177-179
35. J. Vuky J. McCaffrey M. Ginsberg et al. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors Invest New Drugs 18 2000 265-267
36. A. Sandler S. Fox T. Meyers et al. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: A phase I trial Am J Clin Oncol 21 1998 180-184
37. C. Bokemeyer J. Beyer B. Metzner et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer Ann Oncol 7 1996 31-34
38. R.J. Motzer D.F. Bajorin L.H. Schwartz et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors J Clin Oncol 12 1994 2277-2283
39. R.J. Motzer J. Sheinfeld M. Mazumdar et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer J Clin Oncol 18 2000 2413-2418
40. O. Rick C. Bokemeyer J. Beyer et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer J Clin Oncol 19 2001 81-88
41. S. Hinton P. Catalano L.H. Einhorn et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group J Clin Oncol 20 2002 1859-1863
42. D. Pectasides M. Pectasides D. Farmakis et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study Ann Oncol 15 2004 493-497
43. C. Kollmannsberger J. Beyer R. Liersch et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group J Clin Oncol 22 2004 108-114
44. R.J. Motzer M. Mazumdar J. Sheinfeld et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients J Clin Oncol 18 2000 1173-1180
45. G.M. Mead M.H. Cullen R. Huddart et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: A medical research council trial Br J Cancer 93 2005 178-184
46. J. Beyer S. Stenning A. Gerl et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables J Clin Oncol 14 1996 2638-2645
47. J. Beyer S. Stenning A. Gerl S. Fossa W. Siegert High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: A matched-pair analysis Ann Oncol 13 2002 599-605
48. J.L. Pico G. Rosti A. Kramar et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors Ann Oncol 16 2005 1152-1159
49. D.A. Vaena R. Abonour L.H. Einhorn Color. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables J Clin Oncol 21 2003 4100-4104
50. I.A. McNeish E.J. Kanfer R. Haynes et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours Br J Cancer 90 2004 1169-1175
51. J.P. Lotz B. Bui F. Gomez et al. on the behalf of the Groupe d'Etudes des Tumeurs Uro-Genitales (GETUG) Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial Ann Oncol 16 2005 411-418
52. U. De Giorgi T. Demirer H. Wandt et al. Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: The EBMT experience Ann Oncol 16 2005 146-151
53. S.B. Saxman C.R. Nichols L.H. Einhorn Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience J Clin Oncol 12 1994 1390-1393